DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF

Vitiligo is a chronic autoimmune skin disorder where immune T cells, particularly CD8⁺ cytotoxic T cells and regulatory T cells, play a significant role in the destruction of melanocytes. Recent advancements in understanding its pathogenesis have led to the development of targeted therapies, such as Janus kinase (JAK) inhibitors, which have shown therapeutic potential. Additionally, mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) have emerged as promising treatments due to their ability to regulate cytokine secretion and T-cell balance, offering anti-inflammatory effects. The document highlighted the progress in these therapies and emphasized the need for further research into vitiligo treatment.